Exenatide: Dosing Protocols

Prescribing Information#

Exenatide is an FDA-approved prescription medication available as Byetta (immediate-release, twice-daily) and Bydureon BCise (extended-release, once-weekly) for type 2 diabetes. All dosing information below is from FDA-approved prescribing information. Exenatide must be prescribed and supervised by a qualified healthcare provider.

Byetta (Immediate-Release): Twice-Daily Dosing#

Starting Dose#

Initiate at 5 mcg administered subcutaneously twice daily within 60 minutes before the morning and evening meals (or the two main meals, at least 6 hours apart). The 5 mcg dose serves as both a tolerability dose and a therapeutic dose.

Dose Escalation#

After 1 month at 5 mcg BID, the dose may be increased to 10 mcg BID based on clinical response and tolerability. The 10 mcg dose provides additional HbA1c reduction.

Critical Meal-Timing Requirement#

Byetta must be injected within 60 minutes before the morning and evening meals. This timing is essential because:

• The immediate-release formulation produces acute postprandial GLP-1 receptor activation
• The gastric emptying delay effect is most therapeutically relevant when timed with meals
• Postprandial glucose control depends on the temporal relationship between injection and food intake
• Do NOT inject after a meal

Clinical Outcomes (AMIGO Trials)#

• 5 mcg BID: HbA1c reduction of approximately 0.4-0.5%
• 10 mcg BID: HbA1c reduction of approximately 0.8-0.9%
• Body weight reduction of approximately 1.5-3.0 kg over 30 weeks

Bydureon BCise (Extended-Release): Once-Weekly Dosing#

Fixed Dose#

Bydureon BCise is a single fixed dose of 2 mg administered subcutaneously once weekly. No dose titration is required. This simplifies the treatment regimen compared to Byetta.

Administration#

• Inject at any time of day, with or without meals
• Administer on the same day each week
• The day of the week may be changed as long as the last dose was given at least 3 days (72 hours) before
• If a dose is missed, administer as soon as possible within 3 days. If more than 3 days since the missed dose, wait until the next regularly scheduled dose.

Clinical Outcomes (DURATION Trials)#

• 2 mg weekly: HbA1c reduction of approximately 1.3-1.9%
• Body weight reduction of approximately 2.0-3.7 kg over 24-30 weeks
• Bydureon once weekly was shown to be more effective than Byetta twice daily for HbA1c reduction in the DURATION-1 trial (1.9% vs 1.5% at 30 weeks)

Administration Technique#

Byetta Pre-Filled Pen#

Byetta is supplied as a pre-filled pen containing 250 mcg/mL solution. Two pen configurations:

• 5 mcg pen: delivers 60 doses (30-day supply at BID dosing)
• 10 mcg pen: delivers 60 doses (30-day supply at BID dosing)

Injection procedure:

1. Remove pen from refrigeration if stored in refrigerator
2. Attach a new pen needle
3. Dial the dose and inject subcutaneously in the abdomen, thigh, or upper arm
4. Hold for 5 seconds to ensure complete delivery
5. Remove and discard needle

Bydureon BCise Auto-Injector#

Bydureon BCise uses a single-dose auto-injector requiring preparation:

1. Remove auto-injector from refrigerator and allow to reach room temperature (approximately 15 minutes)
2. Shake vigorously for at least 15 seconds to uniformly suspend the microspheres. The mixture should appear cloudy white to off-white.
3. Unlock the auto-injector and place firmly against the injection site (abdomen, thigh, or upper arm)
4. Press the injection button and hold for 15 seconds
5. Discard the used auto-injector

The vigorous shaking step is critical: inadequate mixing results in non-uniform drug delivery.

Storage Requirements#

Byetta#

• Before first use: Refrigerate at 2-8 degrees C (36-46 degrees F)
• After first use: May be kept at room temperature not exceeding 25 degrees C (77 degrees F) for up to 30 days
• Do not freeze. Discard if frozen.
• Protect from light. Keep pen cap on.

Bydureon BCise#

• Store refrigerated at 2-8 degrees C (36-46 degrees F)
• May be stored at room temperature up to 30 degrees C (86 degrees F) for up to 4 cumulative weeks
• Do not freeze
• Store in original packaging to protect from light
• Each auto-injector is single-use

Special Dosing Considerations#

Renal Impairment#

Exenatide is primarily eliminated through renal clearance. Dose adjustments:

• eGFR 30-50 mL/min: Use with caution. No specific dose adjustment but increased monitoring recommended.
• eGFR below 30 mL/min: Not recommended due to limited experience and risk of GI adverse events causing dehydration-related AKI
• End-stage renal disease / dialysis: Not recommended

Hepatic Impairment#

No dose adjustment required. Exenatide is not significantly metabolized by the liver.

Concomitant Insulin or Sulfonylurea#

When adding exenatide to insulin or sulfonylurea therapy, consider reducing the dose of the concomitant medication to reduce hypoglycemia risk.

Switching Between Formulations#

When switching from Byetta to Bydureon BCise, discontinue Byetta and initiate Bydureon BCise on the next scheduled injection day. During the transition period (first 6-7 weeks on Bydureon), postprandial glucose control may temporarily decrease as microsphere steady state has not yet been reached.

Clinical Dosing Outcomes Summary#

Related Reading#

• Exenatide overview and research guide
• Exenatide side effects profile
• Exenatide research evidence